Author information:
(1)From the Vaccine and Infectious Disease Division, Fred Hutchinson Cancer 
Research Center (G.E.G., Z.M., N. Grunenberg, Y.H., D.G., B.P., J.J.K., J.H., 
C.B., S.R., S.T., M.J., M. Sikhosana, M. Andrasik, J.G.K., M.J.M., P.B.G., H.J., 
L.C.), Seattle; the Perinatal HIV Research Unit, Faculty of Health Sciences, 
University of the Witwatersrand (G.E.G., F.L., E.L., B.M., T.P., S.T.), the 
National Institute for Communicable Diseases, National Health Laboratory Service 
(A.P.), and Aurum Institute (C.I., M. Sebe, W.B., P.S., T.A., G. Kobane), 
Johannesburg, Desmond Tutu HIV Centre (L.-G.B., S.K., C.N.N., M. Atujuna), the 
Department of Medicine, Wellcome Centre for Infectious Diseases Research in 
Africa, and Institute of Infectious Disease and Molecular Medicine (G.M., 
A.M.W.), and the Division of Clinical Pharmacology, Department of Medicine 
(L.W.), University of Cape Town, Cape Town, Setshaba Research Centre, Soshanguve 
(M.M., K.S.M.), Mecru Clinical Research Unit, Sefako Mkgatho Health Sciences 
University, Ga-Rankuwa (M.N., M.P.M.), Nelson Mandela Academic Clinical Research 
Unit and Department of Internal Medicine and Pharmacology, Walter Sisulu 
University, Mthatha (T.D., P.M.), the School of Health Systems and Public 
Health, Faculty of Health Sciences, University of Pretoria, Pretoria (S.T.), the 
South African Medical Research Council (G.E.G., D.K., N.S., V.N., G. Kistnasami, 
Z.G.) and the Centre for the AIDS Programme of Research in South Africa, 
University of KwaZulu-Natal (N.N., N. Garrett), Durban, and Qhakaza Mbokodo 
Research Clinic, Ladysmith (P.K., P.B.M.) - all in South Africa; the Vaccine 
Research Program, Division of AIDS, National Institute of Allergy and Infectious 
Diseases, National Institutes of Health, Bethesda (M. Allen), and 
GlaxoSmithKline Vaccines, Rockville (N.K.-T.) - both in Maryland; the Department 
of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory 
University, Atlanta (D.B.); GSK Vaccines, Cambridge, MA (S.W.B.); Sanofi 
Pasteur, Swiftwater, PA (S.P., C.D.G.); GlaxoSmithKline, Siena, Italy (S.P.); 
GlaxoSmithKline, Wavre (M.K.), and GlaxoSmithKline, Rixensart (O.V.D.M.) - both 
in Belgium; and the Graduate Group in Biostatistics and the Center for 
Computational Biology, University of California, Berkeley (N.S.H.).